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Introduction
Dexamethasone (DEX) is a synthetic glucocorticoid which is used to treat a wide variety of medical conditions. It is a potent anti-inflammatory and immunosuppressant, which is metabolised primarily by the liver and undergoes renal excretion (Minagawa et al., 1986 ).
Dexamethasone induces cytochrome P450 genes, such as Cyp3a11 and Cyp2b10 in mice and CYP3A4 in humans Wrighton et al., 1985; Strom et al., 1996; Yanagimoto et al., 1997) . The mechanism of this induction is complex and is mediated by a number of nuclear receptors. For example, the glucocorticoid receptor (GR) is essential for the DEX-mediated induction of Cyp2b proteins in mouse liver, but at high doses the induction of Cyp3a enzymes is mediated by other transcription factors (Schuetz et al., 2000) . In addition, it has been reported that DEX induction of CYP3A4 in human hepatocytes is mediated by several transcription factors (Pascussi et al., 2001) . At low (nmol) concentrations CYP3A4 induction is mediated by a GR-dependent elevation of pregnane X receptor (PXR) expression, while at high (supramicromolar) concentrations DEX directly binds to and activates PXR. In addition, submicromolar concentrations of DEX also enhance the expression of the constitutive androstane receptor (CAR) and the retinoid X receptor-alpha in human hepatocytes (Pascussi et al., 2000a; Pascussi et al., 2000b) .
It has been demonstrated that DEX is a more potent ligand for mouse PXR than the human receptor (Meehan et al., 1988; Moore et al., 2000) and hepatic induction of Cyp3a, but not Cyp2b, expression in mice is PXR-dependent (Schuetz et al., 2000; Scheer et al., 2008) .
CYP3A plays a central role in DEX disposition in human liver as it catalyzes the formation of the two major metabolites, 6α and 6ß-hydroxy-dexamethasone (Gentile et al., 1996) . Indeed, the relatively simple metabolic profile of DEX compared with many other substrates led to the proposal that DEX would be a useful in vivo probe for CYP3A4 activity (Gentile et al., DMD #31872 -5 -to be a significant factor in determining both the metabolism and circulating levels of this glucocorticoid.
DEX can influence the toxicity of other compounds by enzyme induction. For example, pretreatment of rats with DEX (5-20 mg/kg, p.o.) 24h before administration of the antitumor drug yondelis (ET-743) markedly reduced the biochemical and histopathological manifestations of yondelis-induced liver changes (Donald et al., 2003) . This protective effect was speculated to be a consequence of the decreased hepatic exposure to yondelis linked to induction of metabolism by CYP enzymes.
On the other hand, pre-treatment of mice with high doses of DEX (75 mg/kg, ip, for 4 days) increased acetaminophen-induced hepatotoxicity and at this dose DEX was also hepatotoxic by itself (Madhu et al., 1992) . At the therapeutic doses used in humans, DEX is not regarded as a hepatotoxic. There are however some occasional cases in which DEX administration is associated with severe hepatotoxicity. For example, DEX treatment has been associated with methotrexate hepatotoxicity in children in a manner unrelated to changes in methotrexate serum-levels (Wolff et al., 1998 ).
The in vivo factors which determine the metabolism and toxicity of DEX are complex and, because of species differences in its interaction with nuclear receptors, such as CAR, PXR and GR, studies in rodents might not accurately reflect the human situation. In this study we have used mice either deleted or humanized at the Pxr gene locus as well as mice where seven functional Cyp3a genes have been deleted to evaluate the roles of the human receptor and Cyp3a proteins in DEX response. As part of this work we describe the generation of a new and improved humanized PXR model. The data presented demonstrate that mouse and human PXR exhibit marked differences in their in vivo interactions with DEX and the impact of these differences on DEX-hepatotoxicity were analysed in this study.
DMD #31872 -6 -
Materials and Methods
Animal husbandry. Mice were kept in Tecniplast Sealsafe microisolator cages. Food and water were available ad libitum. Light cycles were on a 13:11 h light/dark cycle with the light phasing starting at 06:00 h. Temperature and relative humidity were maintained between 21°C and 23°C and 45% and 65%.
Construction of the targeting vector used for the generation of an improved PXR
humanized mouse line (huPXRi). Intron 6 and 7 of the human PXR gene were amplified by PCR from a bacterial artificial chromosome carrying human PXR and subcloned into the targeting vector used for the generation of the PXR humanised (huPXR) mice previously described (Scheer et al., 2008) , to give rise to the targeting vector depicted in Figure 1 .
Generation and molecular characterisation of huPXRi targeted embryonic stem (ES)
cells. Culture and targeted mutagenesis of ES cells were carried out as previously described (Hogan et al., 1994) . The targeting vector was linearised with NotI and electroporated into a C57BL/6 mouse ES cell line. Of 132 hygromycin resistant and fluorescence negative ES cell colonies screened by standard Southern blot analyses, 12 correctly targeted clones were identified. Six of these were expanded and further analysis by Southern blot analyses with different suitable restriction enzymes and 5' and 3' external probes and an internal hygromycin probe, confirmed that these clones were correctly targeted at both homology arms and didn't carry additional random integrations (data not shown).
Generation and molecular characterisation of PXRi humanized mice. One of the PXRi targeted ES cell clones described above was expanded, injected into BALBc-blastocysts and transferred into foster mothers as previously described (Hogan et al., 1994) . Litters from these fosters were visually inspected and chimerism was determined by hair colour. Highly chimeric animals were used for further breeding in a C57BL/6 genetic background. The DMD #31872 -7 -hygromycin selection cassette was removed in vivo by crossing to an efficient FLP-deleter (FLPe-deleter) strain carrying a transgene that expresses FLPe in the germline (Figure 1 ). The FLPe-deleter has been generated in house on a C57BL/6 genetic background. The PXRi humanized allele was detected by PCR with the primers 5'-GGACTTGCCCATCGAGGAC-3' and 5'-ACAGGATGGAGGGGCAGC-3', giving rise to a 332 bp PCR fragment. PXR knockout (PXR KO) and huPXR mice as described previously (Scheer et al., 2008) were used in addition to the huPXRi mice described here. Homozygously humanized and knockout mice for PXR were used for all studies and WT C57BL/6 animals for control experiments were purchased from Harlan (UK). at 4°C, then the supernant was spun at 13864g (Sorvall F28/13 rotor) for 15mins at 4°C. The resulting supernatant was spun at 82187g (Sorvall F28/13 rotor) for 90mins at 4°C and the microsomal pellets were resuspended in ice-cold SET buffer and stored at -70°C.
Animal and
Immunoblot Analysis. For Western Blot analysis, microsomal protein (5µg) from pooled mouse samples (n=3) was separated by SDS-PAGE, electropheretically transferred to nitrocellulose membranes and probed using an anti-rat CYP3A1 polyclonal Ab and anti-rat CYP2B1/2 polyclonal Ab (BRI, University of Dundee) (Forrester et al., 1992) Cytochrome P450 Enzyme Activity Assays. Activity of Cyp2b10 in hepatic microsomes was monitored using the preferred Cyp2b10 substrate pentoxyresorufin. Pentoxyresorufin dealkyation (PROD) was monitored in a 1cm 3 cuvette containing 66mM Tris-HCl buffer, pH 7.4, microsomes (20 to 50µg) and 1mM pentoxyresorufin. The reactions were initiated by the addition of 50µM NADPH and the rate of fluorescence was measured. As an internal control, each microsomal mixture was spiked with 10µM resorufin.
Dealkylation of 7-benzyloxyquinoline (BQ, 20mM), a Cyp3a11 preferred substrate was measured in liver microsomes (20-50µg) suspended in 66mM Tris-HCl buffer, pH 7.4.
Assays were initiated by the addition of 50µM NADPH to the microsomal reaction and followed using a Hitachi F-4500 fluorescence spectrophotometer with FL Solution 2.0 software. 7-Hydroxyquinoline (7-HQ, 1mM) was used as the internal standard.
Protein concentrations were measured using a modified version of the method of Lowry (Lowry et al., 1951) Statistics. Statistical significance was assessed to determine differences between mouse groups using a two-tailed, paired, Student's t test. The criterion for statistical significance was P < 0.05. 
Results
Generation of the new humanized PXR mouse model. We recently described the generation of a PXR humanized mouse (huPXR) expressing the human receptor under control of the mouse Pxr promoter (Scheer et al., 2008) . The DNA cassette used contained a fusion of exons 2-4, intron 4, exon 5, intron 5, and a fusion of exons 6-9 of the human PXR gene. This huPXR mouse expressed a functional human PXR protein and exhibited the predicted species differences in its interaction with drugs such as rifampicin and dexamethasone. Furthermore, we demonstrated that both the full length and the most abundant splice variants identified in humans, human PXR (hPXR) SV2 (or hPXR.2) were also expressed (Dotzlaw et al., 1999; Hustert et al., 2001; Fukuen et al., 2002) . However, in this model we found that an as yet unidentified splice variant was detected. Further investigation showed that a splice acceptor site was created by the fusion of exon 7 and 8 which led to a variant where exon 5 was spliced out of frame to exon 8, resulting in a premature stop codon in exon 8. As most of the ligandbinding domain is altered, these transcripts either code for a non-functional protein or, though unlikely, maybe even a dominant negative protein interfering with the normally spliced PXR receptor. They also might be degraded by nonsense-mediated decay (see (Schell et al., 2002) for review). As is it is difficult to measure how much of the truncated transcript is degraded, we can't estimate the total amount of transcript wasted by aberrant splicing. Although it is not possible to quantify this effect, a fraction of the human PXR transcript will not code for a functional protein potentially reducing the sensitivity of the model to enzyme inducers.
In order to avoid this possible problem, we have generated a new PXR-humanized mouse line by altering the original targeting vector to include the two additional human introns 6 and 7.
The new PXR-humanized mouse line was generated by a knock-in strategy as shown in Figure 1 , such that a chimeric construct containing the cDNA representing exons 2-4 of human PXR missing the start CTG, genomic sequences in-between exon 4 and 8 and again cDNA of exon 8-9 followed by an SV40 polyA signal was introduced at the ATG of the This article has not been copyedited and formatted. The final version may differ from this version. Comparison of the huPXR and huPXRi sequences obtained by reverse transcription PCR from hepatic mRNA showed that both lines expressed the full length and most abundant human splice isoform hPXR SV2 in the liver. However, the previously observed variant where splicing had occurred between exon 5 to exon 8 was not detected in the huPXRi line. In addition, relative expression levels of hPXR transcripts in male and female livers were quantified by reverse transcriptase PCR (Figure 2 ). Interestingly, human PXR mRNA expression levels were increased by 5.6-fold in male huPXRi mice compared to the huPXR males. In females the expression levels were slightly lower for both genotypes and in huPXRi females relative expression of human PXR mRNA was increased by 4.6-fold relative to huPXR mice of the same sex. The lower transcript levels in the huPXR mouse line might reflect the degradation of a fraction of the transcripts in this mouse line by nonsense-mediated decay. It was not possible to quantify the amount of full length PXR protein because no suitable antibody is available.
Induction profiles of cytochrome P450 Cyp3a and Cyp2b proteins in rifampicin treated
WT, huPXR and huPXRi mice. In order to test if the new PXR model had an altered sensitivity to PXR ligands, we treated WT, huPXR and huPXRi mice with rifampicin (RIF), a compound showing higher affinity for the human versus the mouse receptor (Xie et al., 2000a) . In agreement with our previous findings (Scheer et al., 2008) , a dose of 10 mg/kg body weight resulted in a consistent Cyp3a11 induction in the huPXR mice, but only a marginal induction in the WT ( Figure 3A) . However, in the huPXRi mice the induction at this dose was more pronounced than in both WT and huPXR mice. In order to quantify these differences we measured the band intensities of Cyp3a11 in animals treated with 10 mg/kg This article has not been copyedited and formatted. The final version may differ from this version. RIF relative to the untreated control of the corresponding genotype. The increase in band intensity was 1,8-fold in the WT, 4,5-fold in the huPXR mouse line and 7,7-fold in huPXRi animals. Furthermore, at a maximum dose of 60 mg/kg the Cyp3a11 band intensity in the huPXRi mouse line was 1,9-fold higher compared to huPXR mice and 2,7-fold higher compared to the WT. Therefore, the huPXRi mouse line has an increased sensitivity to RIFmediated Cyp3a11 induction compared to the huPXR mice both in the dose response and the magnitude of induction. The dose dependency exemplifying the difference in sensitivity between WT and huPXRi mice is shown in Figure 3B . The differences observed by Western blotting were also reflected in the metabolism of the Cyp3a11 substrate 7-benzyloxyquinoline (BQ); a significant increase in metabolism was observed at a dose of RIF of 10 mg/kg in huPXRi compared to WT mice ( Figure 3C ). Namely, the increase of BQ metabolism at this dose was 1,5-fold in the WT, 1,9-fold in the huPXR mice and 2,9-fold in huPXRi animals compared to the untreated controls of the corresponding genotype. As reported previously, a slight increase in the basal level of Cyp3a11 expression in both huPXR and huPXRi mice was observed (Scheer et al., 2008) .
Intriguingly, a marked induction of Cyp2b10 expression was observed in huPXRi mice at a dose of 10 mg/kg RIF and a much higher induction at 60 mg/kg ( Figure 3A ). The induction of this protein was substantiated by the marked increase in the Cyp2b10-specific pentoxyresorufin dealkylation (PROD) in the huPXRi mouse line ( Figure 3C ). Consistent with the expression observed in Cyp2b10 protein, no induction of PROD activity was measured in WT and huPXR mice at 10 mg/kg RIF and only a marginal increase is observed at 60 mg/kg. These data demonstrate the higher sensitivity of the new PXR model to induction and consistent with the literature RIF has been reported to be an inducer of CYP2B6 expression in human hepatocytes (Goodwin et al., 2001; Pichard-Garcia et al., 2002) .
This article has not been copyedited and formatted. The final version may differ from this version. Comparison of cytochrome P450 induction by dexamethasone in wild type and humanised mice. Characterisation of the interaction of dexamethasone with PXR is shown in Figure 4 . Cyp3a11 induction in WT mice was observed at much lower doses than in huPXRi mice ( Figure 4A) . For example at a dose of 3 mg/kg a significant induction of Cyp3a11 was observed in WT animals, but not in huPXRi mice. However, a similar level of induction was found at a 10-fold higher dose of 30mg/kg. This was also reflected in the rate of metabolism of the Cyp3a11 substrate BQ at the 30mg/kg dose ( Figure 4B ). We noted that relative to our original huPXR mice, treatment with DEX resulted in a much more marked consistent induction of Cyp3a11 in the new model. At a dose of 10 mg/kg Cyp3a11-induction was only observed in huPXRi, but not in huPXR mice and at higher doses such as 30 mg/kg induction in huPXRi mice was more profound (see also (Scheer et al., 2008) ). Therefore, in addition to an increased sensitivity and different pattern of induction in response to RIF, huPXRi compared to huPXR mice were also more sensitive to the more potent mouse inducer, DEX.
The above effects were shown to be mediated by PXR as no induction of Cyp3a11 was seen in the PXR null animals ( Figure 4A ). In agreement with previous findings Cyp2b10 induction by DEX is comparable between WT, huPXRi and PXR KO mice and therefore is independent of PXR ( Figure 4A ) (Schuetz et al., 2000; Scheer et al., 2008) . The hepatotoxic effect of high doses of DEX (30mg/kg) was also apparent following histological examination of liver sections in all strains. Macrovesicular hepatocellular vaculation that was partly associated with a peripheral dislocation of the usually centrally placed hepatocytic nuclei was observed in most treated mice of the different lines ( Figure 5B) and some individuals displayed necrosis of scattered single cells or subcapsular liver necrosis.
Single hepatocyte necrosis in the treated group was not observed in any of the analyzed WT This article has not been copyedited and formatted. The final version may differ from this version. Figure 6A ). Statistically significant differences in areas under the concentration versus time curve (AUCs) between WT, PXR KO and Cyp3a -/-/Cyp3a13 +/+ mice were also observed ( Figure 6B ). It has been demonstrated that after intraperitoneal administration of an isoformspecific CYP substrate the ratio of the expression level of the corresponding CYP in the liver is inversely proportional to the ratio of the AUCs of the substrate (Lukas et al., 1971; Gibaldi and Perrier, 1982) . Thus, the AUC difference suggested that after induction with DEX, enzymes responsible for DEX metabolism were expressed at lower level in the Cyp3a 
Discussion
As part of this report we have compared the properties of two mouse lines humanized for the transcription factor PXR which only differ in that in the original model (Scheer et al., 2008 ) a cryptic splice acceptor site was generated as part of the vector construction. Although the fulllength human PXR mRNA was expressed in both models and the expression of hPXR was driven off identical promoter sequences, there were some significant differences between these mouse lines in both the level of PXR expression and its capacity to regulate downstream genes in response to ligands such as rifampicin and dexamethasone. This suggests that alternative splicing of PXR can be an important factor in determining the level of functional PXR receptor (Hustert et al., 2001; Fukuen et al., 2002) . What was also particularly interesting was that in the new humanized PXR model rifampicin was a good inducer of Cyp2b10 and that this protein was not induced in either WT or the huPXR mouse line. This indicates that the differential expression of PXR will not only affect the amplitude of induction, but also which genes are induced. The induction of Cyp2b genes by rifampicin is consistent with previous studies showing the induction of CYP2B6 in human hepatocytes by this compound (Goodwin et al., 2001; Pichard-Garcia et al., 2002) . Interestingly, though dexamethasone elevates Cyp3a11-expression in a PXR-dependent manner, Cyp2b10 induction by this compound does not require PXR and might at least in part be the consequence of an enhanced expression of CAR and the retinoid X receptor-alpha in response to DEX (Pascussi et al., 2000a; Pascussi et al., 2000b) . Taken together the data demonstrate that regulation of Cyp2b10 (and possibly CYP2B6 in man) is complex and it involves several transcription factors such as CAR (Honkakoski et al., 1998; Wei et al., 2000) , GR (Schuetz et al., 2000) and PXR (Xie et al., 2000b; Wagner et al., 2005) . Furthermore, depending on the compound the activation of a given receptor like PXR can either be required for Cyp2b10-
induction (RIF) or nonessential (DEX).
This article has not been copyedited and formatted. The final version may differ from this version. The presented studies revealed a hepatotoxic effect of high doses of the glucocorticoid DEX in mice. At 30 mg/kg a statistically significant increase in ALT levels could be observed in WT, huPXR, huPXRi, PXR KO and Cyp3a -/-/Cyp3a13 +/+ mice when compared with their corresponding untreated controls. The liver damaging effect was also confirmed by the induction of macrovesicular hepatocellular vaculation and different degrees of necrosis in histological examination. This effect is in agreement with the previously observed hepatotoxicity of high doses of DEX in mice (Madhu et al., 1992) .
There is currently significant interest in the potential use of humanized and knockout animal models as more reliable predictors of pathways of drug metabolism and chemical safety in man (Cheung and Gonzalez, 2008; Lin, 2008; Scheer et al., 2008) . This is based on the increasing evidence that there are species differences in both nuclear receptors which regulate the expression of drug metabolising enzymes as well as the enzymes themselves. There is also evidence that these differences can lead to both increased sensitivity to some molecules or reduced sensitivity to others such as certain non-genotoxic carcinogens (Zhang et al., 2002; Cheung et al., 2004; Morimura et al., 2006; Gonzalez and Shah, 2008) .
One important facet of chemical safety screening is that molecules, as a consequence of their interaction with nuclear receptors like PXR and CAR can induce their own metabolism or that of other molecules administered concomitantly. This can either result in reduced pharmacological efficacy or, if the parent molecule is toxic, reduced toxicity, or, if the parent molecule is metabolised to a reactive metabolite, increased toxicity. Therefore, species differences in the capacity of compounds to activate rodent or human receptors can result in marked differences in their pharmacological or toxicological effects.
Using a relatively small number of transgenic animals, significant insights into the pathways regulating dexamethasone metabolism and toxicity could be obtained. The doses of DEX required to induce hepatotoxicity are, however, not representative of the therapeutic doses used in humans. Even in shock therapy usually only 4 to 8 mg are injected intravenously and if necessary this is repeated to a total maximum dose of 24 mg. Therefore, the dose of up to 30 mg/kg body weight used in this study exceeds the maximum human dose by two orders of magnitude. In addition, differences in the hepatic blood flow rates between mice and humans might contribute to potential variations in hepatic sensitivity to this glucocorticoid. Nevertheless, these studies exemplify the fact that species differences in the interaction of compounds with PXR can alter the metabolism and potentially the toxicological profile of drugs and chemicals, which could result in differences in the pathways of metabolism and susceptibility to hepatotoxicity between animals and man.
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